Urolithin A Testing Transparency Report
Current Urolithin A products compared by COA visibility, testing disclosure and formal certification rather than marketing language.
Why testing deserves its own score
A product can disclose 500 mg and still tell the buyer very little about identity, potency or contaminants. Testing transparency is therefore scored separately from dose, price and evidence.
Testing comparison
| Product | Testing disclosure | COA | Certifications | Testing score |
|---|---|---|---|---|
| ProHealth Longevity — Full Spectrum Urolithin A | Triple lab tested claim | Visible | GMP-certified facility stated | 9/10 |
| Naturecan — Urolithin A | Yes | Visible | Third-party purity/potency testing; made in Europe | 8/10 |
| Timeline — Mitopure Softgels | Certified | Not captured | FDA GRAS; Clean Label Project; NSF Certified for Sport | 6/10 |
| Timeline — Mitopure Powder | Certified | Not captured | FDA GRAS; Clean Label Project; NSF Certified for Sport | 6/10 |
| Timeline — Mitopure Gummies | Certified | Not captured | FDA GRAS; Clean Label Project; NSF Contents Certified | 6/10 |
| Timeline — Mitopure Softgels Sample | Certified | Not captured | NSF Certified for Sport format family | 6/10 |
| Timeline — Mitopure Powder Sample | Certified | Not captured | NSF Certified for Sport format family | 6/10 |
| Timeline — Mitopure Gummies Sample | Certified | Not captured | NSF Contents Certified format family | 6/10 |
| Urolithin A+ — Urolithin A 1200 mg | Marketplace listing states third-party tested | Not captured | GMP-certified facility stated | 6/10 |
| Renue By Science — Urolithin A+ | Independent product-data source cites accredited testing | Not verified in current official testing library | NSF-certified manufacturing cited by independent product-data source | 6/10 |
| Double Wood — Urolithin A | Yes | Brand states COAs available | cGMP facility stated | 4/10 |
| Nature's Fusions — Nutri Urolithin A | Marketplace listing states third-party tested | Not captured | Not captured | 4/10 |
| Bonerge — StanYouth Urolithin A Raw Ingredient | Quality-control characterization stated | B2B documentation context | FSSC22000; HACCP; ISO22000; Halal; Kosher | 4/10 |
| Codeage — Liposomal Urolithin A | NSF certification stated | Not captured | NSF certification; cGMP facility stated | 2/10 |
| DoNotAge — Urolithin A - 500 mg/day option | Brand quality positioning | Not captured | Not captured | 0/10 |
| DoNotAge — Urolithin A - 1,000 mg/day option | Brand quality positioning | Not captured | Not captured | 0/10 |
What the score cannot prove
A high testing-transparency score does not prove that a product improves muscle function or mitochondrial health. It means the finished commercial item is easier to audit.
Why testing transparency matters
A Urolithin A product can disclose a dose while revealing little about identity, potency, contaminants, or batch verification.
What counts as stronger disclosure
Visible batch COAs, formal certification, potency or purity testing, and clear third-party verification provide more auditability than a generic 'lab tested' statement.
What a COA can and cannot prove
A COA can support identity, potency, or contaminant information for a batch. It does not prove clinical effectiveness.
Certification versus testing
Formal certification programs can impose clearer standards than an unexplained testing claim, but certification still does not prove a health outcome.
Why some products score lower
A lower score can reflect missing public information rather than confirmed poor quality.
How current the evidence should be
Testing information is more useful when it applies to the product and batch currently being sold.
How testing affects recommendations
Testing transparency belongs in product comparisons because buyers purchase finished products, not abstract molecules.
Update policy
Scores should change when brands publish new testing documents, gain certifications, or remove previously visible evidence.
Update trigger 1
For Urolithin A Testing Transparency Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 2
For Urolithin A Testing Transparency Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 3
For Urolithin A Testing Transparency Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 4
For Urolithin A Testing Transparency Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 5
For Urolithin A Testing Transparency Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 6
For Urolithin A Testing Transparency Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 7
For Urolithin A Testing Transparency Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 8
For Urolithin A Testing Transparency Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 9
For Urolithin A Testing Transparency Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.
Update trigger 10
For Urolithin A Testing Transparency Report, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.